Bogdana Schmidt

1 week ago | urologytimes.com | Mark Tyson |Bogdana Schmidt |Sam S. Chang |Aaron Berger

Author(s):,Panelists discuss how precise risk stratification in non–muscle-invasive bladder cancer enables physicians to tailor treatment and surveillance strategies based on individual patient risk profiles. Physician Summary:Effective management of non–muscle-invasive bladder cancer (NMIBC) hinges on precise risk stratification. Accurate assessment of patient risk is foundational, guiding the choice of treatment intensity, surveillance frequency, and decisions around intravesical therapy.

1 week ago | urologytimes.com | Mark Tyson |Bogdana Schmidt |Sam S. Chang |Aaron Berger

Author(s):,Panelists discuss how specific tumor characteristics, such as papillary architecture and presence of carcinoma in situ, guide risk-adapted treatment decisions in non–muscle-invasive bladder cancer. Physician Summary:Specific tumor features—such as papillary architecture and the presence of carcinoma in situ (CIS)—play a critical role in shaping treatment decisions for NMIBC.